同步加量调强放疗联合替莫唑胺对非小细胞肺癌脑转移的治疗效果与MGMT和Tiam1表达的关系  

Relationship between MGMT and Tiam1 Expression in Patients with Brain Metastases from NSCLC Treated with Concurrent Intensity-modulated Radiotherapy Combined with Temozolomide

作　　者：柴丽霞 王嵘 杨世荣 马莉莎 华毛 韩国雄 荀森 CHAI Lixia;WANG Rong;YANG Shirong(The Fifth People's Hospital of Qinghai, Xining Qinghai 810000, China)

机构地区：[1]青海省第五人民医院肿瘤放疗二病区,青海西宁810007

出　　处：《河北医学》2020年第11期1814-1818,共5页Hebei Medicine

基　　金：青海省第五人民医院青年基金科研项目,(编号:2018-QNL-06)。

摘　　要：目的:分析同步加量调强放疗联合替莫唑胺对非小细胞肺癌(NSCLS)脑转移患者的治疗效果与O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)和T淋巴瘤侵袭转移诱导因子1(Tiam1)表达的关系。方法:60例NSCLC脑转移患者采用同步加量调强放疗并同时口服替莫唑胺,采用免疫组化方法检测切除肺脏组织MGMT和Tiam1的表达,分析MGMT和Tiam1的表达情况与患者治疗效果间的关系及生存时间。结果:60例患者中,21例MGMT(+)及Tiam1(+)患者的治疗总有效率(RR)为76.19%,疾病控制率(DCR)为95.23%,16例MGMT(+)及Tiam1(-)患者的治疗RR为25.00%,DCR为81.25%,17例MGMT(-)及Tiam1(+)患者的治疗RR为88.24%,DCR为94.12%,6例MGMT(-)及Tiam1(-)患者的治疗RR为33.33%,DCR为66.67%。60例患者的随访时间为1~45.35个月,随访中位时间为16.75月,中位生存期时间为13个月,1年、2年和3年生存率分别为75.01%、53.86%和25.31%。21例MGMT(+)及Tiam1(+)患者中位生存期时间为13个月,1年、2年和3年生存率分别为64.32%、45.15%和20.33%。16例MGMT(+)及Tiam1(-)患者中位生存期时间为6个月,1年2年和3年生存率分别为33.69%,20.01%和0.00%。17例MGMT(-)及Tiam1(+)患者中位生存期时间为15个月,1年、2年和3年生存率分别为92.05%、74.12%和40.09%。6例MGMT(-)及Tiam1(-)患者中位生存期时间为10个月,1年、2年和3年生存率分别为55.63%,47.35%和18.96%。结论:MGMT和Tiam1在肺癌组织的不同表达与同步加量调强放疗联合替莫唑胺对NSCLS脑转移患者的治疗效果相关。Objective:To analyze the relationship between the efficacy of concurrent radiotherapy combined with temozolomide and the expression of O6 methylguanine DNA methyltransferase(Mgmt)and invasion and metastasis inducing factor 1(Tiam1)in patients with brain metastases from non-small cell lung cancer(NSCLS).Methods:60 NSCLC patients with brain metastasis were treated with simultaneous modulated accelerated radiotherapy and temozolomide,which of the expression of MGMT and Tiam1 in lung tissue was detected by immunohistochemistry and the relationship between the expression of MGMT and Tiam1 and the therapeutic effect and the survival time were analyzed.Results:The relief rate(RR)of 21 patients with MGMT(+)and Tiam1(+)was 76.19%,the disease control rate(DCR)of which was 95.23%;The RR of 16 patients with MGMT(+)and Tiam1(-)were 25.00%,the DCR of which was 81.25%;The RR of 17 patients with MGMT(-)and Tiam1(-)were 88.24%,the DCR of which was 94.12%;The RR of 6 patients with MGMT(-)and Tiam1(-)were 33.33%,and the DCR of which was 66.6%7%.The follow-up time of 60 patients ranged from 1 to 45.35 months,the median follow-up time was 16.75 months and the median survival time was 13 months,where the 1-year,2-year and 3-year survival rates were 75.01%,53.86%and 25.31%,respectively.The median survival time of 21 patients with MGMT(+)and Tiam1(+)was 13 months,where the 1-year,2-year and 3-year survival rates were 64.32%,45.15%and 20.33%,respectively.The median survival time of 16 patients with MGMT(+)and Tiam1(-)was 6 months,where the 1-year,2-year and 3-year survival rates were 33.69%,20.01%and 0.00%,respectively.The median survival time of 17 patients with MGMT(-)and Tiam1(+)was 15 months,where the 1-year,2-year and 3-year survival rates were 92.05%,74.12%and 40.09%,respectively.The median survival time of 6 patients with MGMT(-)and Tiam1(-)was 10 months,where the 1-year,2-year and 3-year survival rates were 55.63%,47.35%and 18.96%,respectively.Conclusion:The different expression of MGMT and Tiam1 in lung cancer is related to the

关 键 词：非小细胞肺癌 同步加量调强放疗 替莫唑胺 O6-甲基鸟嘌呤-DNA甲基转移酶 T淋巴瘤侵袭转移诱导因子1 

分 类 号：R73[医药卫生—肿瘤]